Puma Biotechnology Inc (PBYI) - Price-to-Projected Revenue Ratio

Graphic logo of Puma Biotechnology (PBYI)

Puma Biotechnology relies on resilient raw material supply chains to minimize drug shortages. Management's strategy focuses on expanding the sales markets for its primary oncology drug. The forward P/S ratio demonstrates the impact of these factors on capitalization relative to expected sales, where 1.80 captures the current state of the parameter. The stable legal status of the biopharmaceutical sector protects the company from geopolitical risks.

PBYI (Puma Bio) Forward P/S Multiple history from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for pumabiotechnology.com (PBYI)

- market price and analyst price targets:
Price Chart Puma Biotechnology, Inc.|PBYI - Fair Value Consensus
- market capitalization indicators:
Market Value PBYI|PBYI - Full Business Value
- book value of equity indicators:
Accounting Value per Share Puma Biotechnology|PBYI - Book Capitalization|Market Value to Book Value Ratio pumabiotechnology.com|PBYI - Cumulative Company Assets
- debt burden and liquidity indicators:
Total Debt to Capital Puma Biotechnology|PBYI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Puma Biotechnology, Inc.|PBYI - Aggregate Debt Obligations|Debts to Book Capitalization PBYI|PBYI - Company Long-Term Debt|Company Short-Term Debts Puma Biotechnology|Quick Liquidity pumabiotechnology.com
- net income and valuation multiples indicators:
PBYI - Company Net Income|Future Profit Puma Biotechnology|PBYI - Market Price to Net Income Ratio|Forward P/E Multiple Puma Biotechnology, Inc.|PBYI - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple PBYI|PBYI - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Puma Biotechnology|PBYI - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months pumabiotechnology.com|PBYI - Earnings per share growth this year|Net earnings per share growth forecast for next year Puma Biotechnology
- total revenue and sales volume data:
PBYI - Company Total Revenue|Company Projected Revenue Puma Biotechnology, Inc.|PBYI - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio PBYI
Summary company analysis:Puma Biotechnology Inc PBYI
Product sample of Puma Bio

Driven by exclusive patents for Nerlynx and high R&D expenditures, Puma Biotechnology (PBYI) creates significant barriers to entry for competitors within the stringent FDA regulatory environment. By analyzing the company's forward P/S dynamics, investors can compare current market capitalization with expected revenue, allowing them to filter out random market noise and determine the business's fair value relative to projected sales volumes.

Who Puma Biotechnology competes with

Price-to-Projected Revenue Ratio Olema OLMA|Forward Price to Sales GLSI|ZNTL - Price-to-Projected Revenue Ratio|Future Price to Revenue MGNX|PSTV (plustherapeutics.com) - Forward Price-to-Revenue Multiple|Processa Pharmaceuticals, Inc. (PCSA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Eagle Pharmaceuticals Inc.